How a US regulator can encourage new science

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 5, 2009, Pages 471-472

  Throckmorton, D C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; NEPHROTOXICITY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCIENCE; UNITED STATES;

ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL MARKERS; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70350240009     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.188     Document Type: Note

References (3)

1. Goodsaid, F.M. et al. Novel biomarkers of acute kidney toxicity. Clin. Pharmacol. Ther. 86, 490-496 (2009).
2. Hutt, P.B. Five moral imperatives of government regulation. Hastings Center Report 10, 29-31 (1980).
3. Sparrow, M.K. The Regulatory Craft (Brookings Institute Press, Washington DC, 2000).